Blog

    • August 19, 2019

    Capsule Pharmacy 'Dear Doctor' Interview Series: Sara Nayeem

    *Interview of Sara Nayeem by Maya De La Rosa-Cohen; originally published as part of the Capsule 'Dear Doctor' Series, which highlights women physicians working throughout the field of healthcare. Dr. Sara Nayeem was selected three times as one of GrowthCap’s Top 40 Under 40 Growth Investors. Having earned her MD and MBA simultaneously from Yale University and worked within Merrill Lynch’s Global Healthcare Group, today she uses her knowledge and experience in both medicine and business…

  • Tiburio: Investing in Traditional Drug Development in the Era of Big Science Platforms

    For the past ten years I have been a biopharma investor at NEA, and in that time I have witnessed the drug industry truly enter the genomic age. With technologies such as gene and mRNA therapy, gene editing, CAR-T and other cell therapies, we are living in a time of unprecedented potential (and peril, as demonstrated by Chinese researcher He Jiankui’s rogue experimentation with gene editing on two human embryos). The public markets (and in some cases, strategic acquirors) have valued these…

  • Looking Beyond the Numbers in Women's Reproductive Medicine

    3.9 million births were recorded in the US in 2013, according to the CDC, down 1% from previous years. Of those, 11.4% were premature births. According to the American Society of Reproductive Medicine (ASRM), preterm birth is one of the primary causes of perinatal morbidity and mortality, and the Institute of Medicine estimates that preterm births cost the healthcare system $26 billion annually. 10%. This is what the ASRM estimates is the percentage of women who suffer from endometriosis. Of…

    • October 28, 2015

    Calling Out True Positives: NEA Invests in Innovative Oncology Diagnostics Company, PGDx

    C-3PO: “Sir, the possibility of successfully navigating an asteroid field is approximately three thousand, seven hundred and twenty to one.” Han Solo: “Never tell me the odds!" - From Star Wars: Episode V - The Empire Strikes Back (1980) The paradigm for treating cancer is evolving incredibly rapidly today. New targeted agents, immuno-oncology, and combination treatment strategies are increasing in availability and price at an accelerating rate, yet predicting any given patient’s response…

  • Vtesse: First Spin-out from Rare Disease Accelerator Cydan

    Today Vtesse, a newly formed biopharma company, announced that it has raised $25 million to develop novel treatments for rare diseases. It’s a significant milestone for several reasons, first and foremost because the funds will enable Vtesse to advance clinical study of VTS-270 for the treatment of a devastating genetic rare disease called Niemann-Pick Disease Type C (NPC). Currently there is no approved treatment for this lysosomal storage disease (LSD) affecting an estimated one in 100,000 to…